No Detail Found!

Dose-Dependent Effects and Safety Assessment of Inactivated COVID-19 Vaccine: A Comprehensive Preclinical Study

Author(s)
Kivilcim Sonmez Istanbul University-Cerrahpaşa Veterinary Faculty, Department of Pathology,Avcilar/Istanbul,Turkey
Engin Alp Onen Kocak Pharmaceuticals, Vaccine and Biotechnology R&D, Organize Sanayi Bölgesi,Kapakli/Tekirdag,Turkey
Ozge Erdogan Bamac Istanbul University-Cerrahpaşa Veterinary Faculty, Department of Pathology,Avcilar/Istanbul,Turkey
Funda Yildirim Istanbul University-Cerrahpaşa Veterinary Faculty, Department of Pathology,Avcilar/Istanbul,Turkey
Srinivas Bezawada Kocak Pharmaceuticals, Vaccine and Biotechnology R&D, Organize Sanayi Bölgesi,Kapakli/Tekirdag,Turkey
Kozet Avanus Istanbul University-Cerrahpaşa Veterinary Faculty, Department of Animal Breeding & Husbandry,Avcilar/Istanbul,Turkey
Necati Ozturk Istanbul University-Cerrahpasa Graduate Education Institute,Avcilar/Istanbul,Turkey
Abstract
Currently, researchers are working to develop new vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causative agent of COVID-19. This study assesses the effectiveness and safety of the inactivated SARS-CoV-2 vaccine candidate KOCAK-19 in Balb/c and K18 hACE2 transgenic mice. Different groups of mice were administered varying doses of the vaccine (4µg, 6µg, and 8µg), followed by exposure to SARS-CoV-2. Utilizing two distinct mouse models allowed for a thorough evaluation of both general immune responses (Balb/c) and human-like susceptibility to SARS-CoV-2 (K18 hACE2), enhancing the findings' relevance. Statistical analysis was conducted using the Kruskal-Wallis and Dunn's tests, with significance at P<0.05. The results emphasize the protective effects of vaccination against severe lung injury, vascular damage, and testicular atrophy. KOCAK-19 vaccination significantly decreases tracheal epithelial hyperplasia, vascular injury, perivascular lymphoid infiltration, microthrombosis, and severe haemorrhage. However, higher vaccine doses are linked to increased bronchial hyperplasia, excessive secretion, and localized inflammatory responses. The vaccinated groups showed less testicular atrophy, highlighting the vaccine's protective role in reproductive health. The study underlines optimizing vaccine dosages to balance immune protection and potential adverse effects. These results offer important preclinical data to improve inactivated vaccine formulations, aiding the development of safer and more effective COVID-19 vaccination strategies.
Publication Details
Page(s) 605-617
Published Journal: Pakistan Veterinary Journal, Volume: 45, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
Histopathology, K18 hACE2, Inactivated SARS-CoV-2 vaccine, Transgenic mice
References
Bhimraj A,Morgan RL,Hirsch SA .2024 .Infectious Diseases Society of America guidelines on treating and managing patients with COVID-19. Clin Infect Dis: ciae435., : .
Chen Z,Yuan Y,Hu Q .2024 .SARS-CoV-2 immunity in animal models. Cell Mol Immunol, 21 : 119-133.
Corbett KS,Flynn B,Foulds KE .2020 .Evaluation of the mRNA1273 vaccine against SARS-CoV-2 in non-human primates. NEJM, 383(16) : 1544-1555.
Fan C,Wu Y,Rui X .2022 .Animal models for COVID-19: advances, gaps and perspectives. Sig Transd Targ Ther, 7(1) : 220.
Fumagalli V,Ravà M,Marotta D .2022 .Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Sci Immunol, 7 : eabl9929.
Giannakopoulos S,Strange DP,Jiyarom B .2023 .In vitro evidence against productive SARS-CoV-2 infection of human testicular cells: Bystander effects of infection mediate testicular injury. PLoS Pathog, 19(5) : e1011409.
Gorbalenya AE,Baker SC,Baric RS .2020 .The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 5(4) : 536-544.
Guebre-Xabier M,Patel N,Tian JH .2020 .NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine, 38(50) : 7892-7896.
Guo Y,Dong Y,Zheng R .2024 .Correlation between viral infections in male semen and infertility: A literature review. Virol J, 21 : 167.
Hoffmann M,Kleine-Weber H,Schroeder S .2020 .SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2) : 271-280.
Javadzadeh M,Moghadam FR,Erfanifar E .2024 .Evaluation of female infertility and viral diseases: A systematic review of coronaviruses. Sex Disabil, 42(4) : 567-589.
Jiang RD,Liu MQ,Chen Y .2020 .Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell, 182(1) : 50-58.
Kruglov AA,Bondareva MA,Gogoleva VS .2024 .Inactivated whole virion vaccine protects K18-hACE2 Tg mice against the Omicron SARS-CoV-2 variant via cross-reactive T cells and nonneutralizing antibody responses. Eur J Immunol, 54(3) : e2350664.
Kozlovskaya LI,Piniaeva AN,Ignatyev GM .2021 .Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Micro Infec, 10(1) : 1790-1806.
Lelis F,Byk LA,Pustylnikov S .2023 .Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models. Sci Rep, 13 : 21172.
Li Z,Xiang T,Liang B .2021 .Characterization of SARS-CoV-2- Specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting. Front Immunol, 12 : 802858.
Liu J,Budylowski P,Samson R .2022 .Preclinical evaluation of a SARSCoV-2 mRNA vaccine PTX-COVID19-B. Sci Adv, 8(3) : eabj9815.
Lu J,Tan S,Gu H .2024 .Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies. Emerg Micro Infec, 13(1) : 2321994.
MacDonald NE .2015 .Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33(34) : 4161-4164.
Muñoz-Fontela C,Dowling WE,Funnell SGP .2020 .. Animal models for COVID-19. Nature, 586(7830) : 509-515.
Munshi I,Khandvilkar A,Chavan SM .2021 .An overview of preclinical animal models for SARS-CoV-2 pathogenicity. Indian J Med Res, 153(1) : 17-25.
Oladunni FS,Park JG,Pino PA .2020 .Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun, 11(1) : 6122.
Onen EA,Sonmez K,Yildirim F .2022 .Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of COVID-19 disease. All Life, 15(1) : 771-793.
Patone M,Handunnetthi L,Saatci D .2021 .Neurological complications after first dose of COVID-19 vaccines and SARSCoV-2 infection. Nat Med, 27(12) : 2144-2153.
Patone M,Thomas K,Hatch R .2021 .Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: An observational cohort study. Lancet Infect Dis, 21(11) : 1518-1528.
Sun SH,Chen Q,Gu HJ .2020 .A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe, 28(1) : 124-133.
Suthar M,Manning KE,Ellis ML .2025 .-adapted COVID19 vaccine improves neutralising activity against the XEC variant. Lancet Infect Dis, 25(3) : e122-e123.
Tanriover MD,Doğanay HL,Akova M .2021 .Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 398(10296) : 213-222.
Ulbegi PH .2023 .Comparison of mouse species in an in vivo SARS-CoV2 challenge model. Kafkas Univ Vet Fak Derg, 29(6) : 689-695.
Vogel AB,Kanevsky I,Che Y .2021 .BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 592(7853) : 283-289.
Winkler ES,Bailey AL,Kafai NM .2020 .SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol, 21(11) : 1327-1335.
Wu Z,Hu Y,Xu M .2021 .Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 21(6) : 803-812.
Yinda CK,Port JR,Bushmaker T .2021 .-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog, 17(1) : e1009195.
Yu J,Tostanoski LH,Peter L .2020 .DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 369(6505) : 806-811.
Zhang Y,Zeng G,Pan H .2020 .Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. Lancet Infect Dis, 21(2) : 181-192.
0

Citations

0

Downloads

51

Views